Logo image of CALC

CALCIMEDICA INC (CALC) Stock Price, Quote, News and Overview

NASDAQ:CALC - Nasdaq - US38942Q2021 - Common Stock - Currency: USD

3.8  +0.11 (+2.98%)

CALC Quote, Performance and Key Statistics

CALCIMEDICA INC

NASDAQ:CALC (7/25/2025, 4:30:02 PM)

3.8

+0.11 (+2.98%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High5.97
52 Week Low1.42
Market Cap53.09M
Shares13.97M
Float11.67M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-07 2025-08-07/amc
IPO09-25 2020-09-25


CALC short term performance overview.The bars show the price performance of CALC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 50 100 150

CALC long term performance overview.The bars show the price performance of CALC in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 2 -2 4 6 8

The current stock price of CALC is 3.8 USD. In the past month the price increased by 167.13%. In the past year, price decreased by -3.55%.

CALCIMEDICA INC / CALC Daily stock chart

CALC Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 59.06 770.22B
JNJ JOHNSON & JOHNSON 16.83 404.94B
NVO NOVO-NORDISK A/S-SPONS ADR 19.38 318.59B
NVS NOVARTIS AG-SPONSORED ADR 13.3 227.85B
AZN ASTRAZENECA PLC-SPONS ADR 16.7 225.28B
MRK MERCK & CO. INC. 10.87 212.71B
PFE PFIZER INC 7.72 140.94B
SNY SANOFI-ADR 11 122.65B
BMY BRISTOL-MYERS SQUIBB CO 6.6 98.56B
GSK GSK PLC-SPON ADR 8.49 76.81B
ZTS ZOETIS INC 25.27 67.73B
TAK TAKEDA PHARMACEUTIC-SP ADR 60.33 45.23B

About CALC

Company Profile

CALC logo image CalciMedica, Inc. operates as a biopharmaceutical company. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2020-09-25. The firm focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The firm's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The firm is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).

Company Info

CALCIMEDICA INC

505 Coast Boulevard South, Suite 307

La Jolla CALIFORNIA US

Employees: 14

CALC Company Website

CALC Investor Relations

Phone: 18589525500

CALCIMEDICA INC / CALC FAQ

What is the stock price of CALCIMEDICA INC today?

The current stock price of CALC is 3.8 USD. The price increased by 2.98% in the last trading session.


What is the ticker symbol for CALCIMEDICA INC stock?

The exchange symbol of CALCIMEDICA INC is CALC and it is listed on the Nasdaq exchange.


On which exchange is CALC stock listed?

CALC stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CALCIMEDICA INC stock?

10 analysts have analysed CALC and the average price target is 14.79 USD. This implies a price increase of 289.21% is expected in the next year compared to the current price of 3.8. Check the CALCIMEDICA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CALCIMEDICA INC worth?

CALCIMEDICA INC (CALC) has a market capitalization of 53.09M USD. This makes CALC a Micro Cap stock.


How many employees does CALCIMEDICA INC have?

CALCIMEDICA INC (CALC) currently has 14 employees.


Should I buy CALCIMEDICA INC (CALC) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CALCIMEDICA INC (CALC) stock pay dividends?

CALC does not pay a dividend.


When does CALCIMEDICA INC (CALC) report earnings?

CALCIMEDICA INC (CALC) will report earnings on 2025-08-07, after the market close.


What is the Price/Earnings (PE) ratio of CALCIMEDICA INC (CALC)?

CALCIMEDICA INC (CALC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.6).


What is the Short Interest ratio of CALCIMEDICA INC (CALC) stock?

The outstanding short interest for CALCIMEDICA INC (CALC) is 0.92% of its float. Check the ownership tab for more information on the CALC short interest.


CALC Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to CALC. When comparing the yearly performance of all stocks, CALC is one of the better performing stocks in the market, outperforming 95.09% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CALC Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to CALC. CALC may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CALC Financial Highlights

Over the last trailing twelve months CALC reported a non-GAAP Earnings per Share(EPS) of -1.6. The EPS increased by 25.58% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -74.45%
ROE -173.33%
Debt/Equity 0.79
Chartmill High Growth Momentum
EPS Q2Q%-3700%
Sales Q2Q%N/A
EPS 1Y (TTM)25.58%
Revenue 1Y (TTM)N/A

CALC Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to CALC. The Buy consensus is the average rating of analysts ratings from 10 analysts.


Ownership
Inst Owners57.77%
Ins Owners11.21%
Short Float %0.92%
Short Ratio2.46
Analysts
Analysts84
Price Target14.79 (289.21%)
EPS Next Y-27.5%
Revenue Next YearN/A